Barclays Downgrades Terns Pharma to Equal-Weight, Lowers Price Target to $53

Benzinga Newsdesk www.benzinga.com Negative 92.8%

Neg 92.8% Neu 0% Pos 0%

Barclays analyst Etzer Darout downgrades Terns Pharma (NASDAQ:TERN) from Overweight to Equal-Weight and lowers the price target from $56 to $53.